Introduction: What Matters in Blood–Brain Barrier Research
As populations age and consumers seek support for sustained mental performance, cognitive health has become an important area of functional product development. Lion’s mane (Hericium erinaceus) is one of the most recognized mushroom ingredients in this category. For B2B product teams, however, the decisive question is not simply whether lion’s mane is included, but which raw-material form is used, which marker compounds are quantified, and whether quality can be reproduced from batch to batch.
Research on lion’s mane has examined compounds associated with nerve growth factor (NGF) pathways. The blood–brain barrier (BBB) restricts the passage of many substances into the brain, making molecular characteristics and evidence quality central to ingredient evaluation. Erinacine A is a cyathane diterpenoid found primarily in lion’s mane mycelium and has been investigated in preclinical studies for its ability to cross the BBB and its potential relevance to neurological and cognitive health.
For ingredient buyers and formulation teams, reliable mycelial cultivation, quantitative testing, and consistent erinacine A specifications are therefore practical criteria when selecting a biotechnology partner.
How Do Submerged and Solid-State Cultivation Differ?
Erinacine A is primarily associated with the mycelial stage of lion’s mane. Raw materials on the market may be derived from fruiting bodies, fruiting-body extracts, or mycelium, and each format has a different composition and specification strategy. Brands should therefore assess the material source, cultivation process, analytical method, marker-compound specification, and batch consistency—not cultivation method alone.
Fruiting-Body Extract vs. New Bellus Lion’s Mane Mycelium
| Evaluation criterion |
Lion’s mane fruiting-body extract |
New Bellus lion’s mane mycelium |
| Raw-material source |
Fruiting bodies extracted and concentrated under product-specific conditions |
Lion’s mane mycelium |
| Common marker compounds | Often polysaccharides, beta-glucans, or hericenones, depending on specification | Erinacine A as a key marker compound |
| Erinacine A | Generally not detected or present at very low levels in fruiting bodies; actual test results should be reviewed | Tested and standardized to at least 0.5% erinacine A |
| Cultivation and processing | Quality depends on fruiting-body source, cultivation conditions, extraction, and concentration | Mycelium cultivated in a closed system using Patented Submerged Fermentation |
| Process control | Requires review of source, solvents, extraction conditions, and concentration method | Temperature, dissolved oxygen, pH, and other cultivation parameters can be closely monitored |
Solid-state mycelial materials may contain residual grain substrate, which can dilute target compounds and complicate standardization. Submerged fermentation uses controlled culture conditions in closed fermentation vessels, allowing key process parameters to be monitored and optimized for mycelial growth and erinacine A production. The final assessment should still be based on the finished ingredient’s analytical specification and quality documentation.
→Industry Feature: Comparing Mushroom Production Technologies
HE12: Scientific Characterization and Regulatory Documentation
In the B2B dietary-supplement market, analytical data, safety documentation, and regulatory readiness help product teams evaluate ingredient suitability. HE12, a lion’s mane mycelium ingredient developed by New Bellus, combines controlled fermentation with a defined erinacine A specification.
→New Bellus Lion’s Mane Mycelium Completes the U.S. FDA NDI Notification Process
1. U.S. FDA NDI Notification Process
HE12 has completed the U.S. Food and Drug Administration’s New Dietary Ingredient (NDI) notification process. The FDA’s no-objection response relates to the safety information and proposed conditions of use presented in the notification; it does not constitute approval or endorsement of efficacy. For brands developing products for the U.S. market, this documentation can support ingredient safety and regulatory assessments under the stated conditions of use.
→How Rigorous NDI Safety Standards Support Quality and Market Planning for Supplement Brands
2. Quantitative Testing and Research Support
Each batch of HE12 is analyzed by high-performance liquid chromatography (HPLC) to verify its erinacine A specification. This quantitative approach gives R&D, quality, and procurement teams a clearer basis for formulation calculations and batch-to-batch control.
Preclinical research in aging mice suggests that H. erinaceus mycelium and erinacine A may have potential relevance to spatial learning under the study conditions. These findings provide a research basis for further development but should not be interpreted as confirmed human cognitive benefits.
Reference: Tsai, Y.-C., et al. (2019). “Hericium erinaceus Mycelium and Its Isolated Compound, Erinacine A, Ameliorate High-Fat High-Sucrose Diet-Induced Metabolic Dysfunction and Spatial Learning Deficits in Aging Mice.” Journal of Medicinal Food, 22(5), 469–478.
Formulation Guide: Building Products Around Erinacine A
For R&D teams and formulators, the value of erinacine A-standardized lion’s mane mycelium lies in combining a defined core ingredient with complementary ingredients selected for the target market, dosage form, evidence base, and local regulatory requirements.
1. Complementary Ingredient Concepts
Mental clarity and focus concept
- Core ingredient: HE12 lion’s mane mycelium, providing standardized erinacine A
- Potential complementary ingredients: phosphatidylserine (PS), ginkgo extract, and B vitamins
- Development rationale: These ingredients address different aspects of a cognitive-health positioning. Final claims and dosage levels should be determined according to supporting evidence, ingredient specifications, and regulations in the target market.
Relaxation and nighttime wellness concept
- Core ingredient: HE12 lion’s mane mycelium
- Potential complementary ingredients: L-theanine, GABA, and ashwagandha
- Development rationale: This combination may support a broader relaxation or nighttime-wellness concept. Compatibility, dosage, safety, sensory performance, and permitted claims require product-specific evaluation.
2. Dosage Forms and Flavor Masking
Lion’s mane mycelium has inherent sensory and physical characteristics. When developing beverages, jellies, or other liquid and semi-solid formats, formulators should evaluate dispersibility, mouthfeel, aroma, flavor, and active-compound stability.
New Bellus has experience applying lion’s mane mycelium in multiple product formats. Based on the target dosage form and formulation requirements, the team can support optimization of inclusion level, dispersion, texture, and flavor for liquid sachets, functional jelly sticks, instant powders, tablets, and capsules.
Appropriate flavor masking, aroma balancing, and ratio optimization can reduce the sensory impact of mushroom notes while maintaining the intended ingredient specification and product positioning.
Conclusion
As the cognitive-health category matures, brands need more than a label claim that lion’s mane is present. Ingredient identity, quantitative specifications, safety documentation, process control, and formulation feasibility provide a stronger foundation for differentiated product development.
With Patented Submerged Fermentation, erinacine A standardization, and integrated B2B development capabilities, New Bellus supports brands from raw-material selection through dosage-form and flavor optimization.
Looking for technical specifications or formulation support? Contact Us
FAQ
A: They differ primarily in source and chemical profile. Hericenones are associated mainly with the fruiting body of lion’s mane, whereas erinacine A is a small cyathane diterpenoid found primarily in the mycelium. Preclinical research has investigated erinacine A’s ability to cross the BBB and its potential neurological relevance. Product evaluation should consider the specific compound, analytical method, dose, and level of supporting evidence.
A: Solid-state cultivation commonly uses grain-based substrates, which may remain in the harvested material and affect composition. New Bellus uses Patented Submerged Fermentation to cultivate mycelium in a closed, controlled system without a grain-based solid substrate. Monitoring parameters such as temperature, dissolved oxygen, and pH supports process control and batch consistency, while finished-product testing verifies the erinacine A specification.